Cargando…

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects

The pharmacokinetics, pharmacodynamics, tolerability, and food effect of cenerimod, a potent sphingosine-1-phosphate subtype 1 receptor modulator, were investigated in three sub-studies. Two double-blind, placebo-controlled, randomised studies in healthy male subjects were performed. Cenerimod was a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Juif, Pierre-Eric, Baldoni, Daniela, Reyes, Maribel, Wilbraham, Darren, Febbraro, Salvatore, Vaclavkova, Andrea, Hoch, Matthias, Dingemanse, Jasper
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751239/ https://www.ncbi.nlm.nih.gov/pubmed/29211013 http://dx.doi.org/10.3390/ijms18122636

Ejemplares similares

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P(1)R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects
por: Juif, Pierre‐Eric, et al.
Publicado: (2020)

Lack of Effect of Cenerimod, a Selective S1P(1) Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive
por: Juif, Pierre-Eric, et al.
Publicado: (2022)

Biocomparison of Three Formulations of the S1P(1) Receptor Modulator Ponesimod in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2015)

Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
por: Dingemanse, Jasper, et al.
Publicado: (2013)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Cardiodynamic Interactions between Two S1P(1) Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects
por: Juif, Pierre-Eric, et al.
Publicado: (2019)

Influence of Rifampin‐Mediated Organic Anion‐Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan
por: Juif, Pierre‐Eric, et al.
Publicado: (2019)

First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
por: Hermann, Viktoria, et al.
Publicado: (2019)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies
por: Brown, Karen, et al.
Publicado: (2018)

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects
por: Wilbraham, Darren, et al.
Publicado: (2020)

Attenuation of murine sclerodermatous models by the selective S1P(1) receptor modulator cenerimod
por: Kano, Miyu, et al.
Publicado: (2019)

Effects of multiple-dose ponesimod, a selective S1P(1) receptor modulator, on lymphocyte subsets in healthy humans
por: Jurcevic, Stipo, et al.
Publicado: (2016)

Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol
por: Tsai, Max, et al.
Publicado: (2020)

Cenerimod, a novel selective S1P(1) receptor modulator with unique signaling properties
por: Piali, Luca, et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects
por: Guérard, N., et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
por: Cong, Duanduan, et al.
Publicado: (2022)

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
por: Juif, Pierre-Eric, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects
por: Yoon, Seonghae, et al.
Publicado: (2015)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
por: Wang, Shining, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
por: He, Xuemei, et al.
Publicado: (2022)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
por: Hu, Yingying, et al.
Publicado: (2023)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
por: Dolder, Patrick C., et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
por: Fedyk, Eric R., et al.
Publicado: (2020)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers
por: Al‐Karagholi, Mohammad Al‐Mahdi, et al.
Publicado: (2021)

Preclinical to clinical translation of cenerimod, a novel S1P(1) receptor modulator, in systemic lupus erythematosus
por: Strasser, Daniel S, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
por: Peterschmitt, M. Judith, et al.
Publicado: (2020)

Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
por: Chen, Xia, et al.
Publicado: (2015)

Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects
por: Dolder, Patrick C., et al.
Publicado: (2017)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists
por: Henrich, Andrea, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
por: Shen, Zancong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jfav56lrj18nh9eur1geb66it2